Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
2minutemedicine.com2d
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
The American Journal of Managed Care2d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
healthday3d
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according ...
The American Journal of Managed Care4d
PROSPERO Identifies Key Risk Factors for Gallstones in Crohn Disease
The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...